Skip to main content
Journal cover image

Randomized open-label phase II tril of aprepitant plus ondansetron compared to ondansetron alone in prevention of chemotherapy-induced-nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.

Publication ,  Conference
Weant, EH; Woodring, S; Randazzo, D; Friedman, H; Desjardins, A; Vlahovic, G; Healy, P; Herndon, J; McSherry, F; Lipp, E; Miller, E; Cone, C ...
Published in: Supportive Care in Cancer

PS060

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Supportive Care in Cancer

DOI

ISSN

0941-4355

Volume

25

Issue

2

Start / End Page

S128 / S128

Location

Washington, DC

Publisher

Springer (part of Springer Nature)

Conference Name

MASCC/ISOO 2017 Annual Meeting

Related Subject Headings

  • Oncology & Carcinogenesis
  • 17 Psychology and Cognitive Sciences
  • 11 Medical and Health Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Weant, E. H., Woodring, S., Randazzo, D., Friedman, H., Desjardins, A., Vlahovic, G., … Afrronti, M. L. (n.d.). Randomized open-label phase II tril of aprepitant plus ondansetron compared to ondansetron alone in prevention of chemotherapy-induced-nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. In Supportive Care in Cancer (Vol. 25, pp. S128–S128). Washington, DC: Springer (part of Springer Nature). https://doi.org/10.1007/s00520-017-3704-x
Weant, Erin H., Sarah Woodring, Din Randazzo, Henry Friedman, Annick Desjardins, Gordana Vlahovic, Patrick Healy, et al. “Randomized open-label phase II tril of aprepitant plus ondansetron compared to ondansetron alone in prevention of chemotherapy-induced-nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.” In Supportive Care in Cancer, 25:S128–S128. Springer (part of Springer Nature), n.d. https://doi.org/10.1007/s00520-017-3704-x.
Weant EH, Woodring S, Randazzo D, Friedman H, Desjardins A, Vlahovic G, et al. Randomized open-label phase II tril of aprepitant plus ondansetron compared to ondansetron alone in prevention of chemotherapy-induced-nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. In: Supportive Care in Cancer. Springer (part of Springer Nature); p. S128–S128.
Weant, Erin H., et al. “Randomized open-label phase II tril of aprepitant plus ondansetron compared to ondansetron alone in prevention of chemotherapy-induced-nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide.Supportive Care in Cancer, vol. 25, no. 2, Springer (part of Springer Nature), pp. S128–S128. Manual, doi:10.1007/s00520-017-3704-x.
Weant EH, Woodring S, Randazzo D, Friedman H, Desjardins A, Vlahovic G, Healy P, Herndon J, McSherry F, Lipp E, Miller E, Cone C, Kim J-Y, Southerland C, Brown C, Carter M, Johnson MO, Peters K, Afrronti ML. Randomized open-label phase II tril of aprepitant plus ondansetron compared to ondansetron alone in prevention of chemotherapy-induced-nausea-vomiting (CINV) in glioma patients receiving adjuvant temozolomide. Supportive Care in Cancer. Springer (part of Springer Nature); p. S128–S128.
Journal cover image

Published In

Supportive Care in Cancer

DOI

ISSN

0941-4355

Volume

25

Issue

2

Start / End Page

S128 / S128

Location

Washington, DC

Publisher

Springer (part of Springer Nature)

Conference Name

MASCC/ISOO 2017 Annual Meeting

Related Subject Headings

  • Oncology & Carcinogenesis
  • 17 Psychology and Cognitive Sciences
  • 11 Medical and Health Sciences